Low- and high-risk groups showed distinct responses to immunotherapy and predictive drug half-maximal inhibitory concentration values across 12 drugs. A risk model comprised of 18 mitochondria-related ...

Evaluating the impact of environmental factors on CLL risk presents unique challenges, including the extended latency period between exposure and disease manifestation, as well as the uncertainty ...

All patients presented to the hospital with acute myelitis in the form of weakness in the arms and legs but no concurrent visual complaints. A team of researchers from Ethiopia presented a case series ...

All 5 patients who switched from eculizumab remained relapse-free while being treated with satralizumab. Satralizumab after eculizumab is effective and well tolerated in patients with neuromyelitis ...

Adjusted analysis found no statistically significant difference in grade 3+ hematologic adverse events between the older and younger cohorts. Standard frontline rituximab, cyclophosphamide, ...

Researchers and physicians should leverage the information available via the digitization of health records to further improve care in HDFN. The digital revolution in medicine can be said to have ...

While immune thrombocytopenia (ITP) is different for everyone, there is a commonality: most people never heard of ITP before their diagnosis. On my illness journey, I’ve learned that there are 2 very ...

Patients with early-stage PBC and ductopenia had reduced biochemical response to ursodeoxycholic acid treatment. Ductopenia is a significant risk factor for worse biochemical profiles and poor ...

The novel anti-IL-36 receptor monoclonal antibody recibokibart demonstrated favorable safety and efficacy in treating patients with acute generalized pustular psoriasis (GPP) in a phase 1b study ...

Secukinumab was employed because of the severity of the symptoms and the potential adverse effects of methotrexate and cyclosporine. A case of pediatric generalized pustular psoriasis (GPP) was ...

Bimekizumab targets IL-17A, IL-17F, and IL-17-AF, unlike other treatments that target only IL-17A. A patient with concurrent generalized pustular psoriasis (GPP), psoriatic arthritis, and plaque ...

A potential association of IgG4-RD with malignancy has been reported, and it remains an open question whether there is an etiologic link between IgG4-RD and the neoplastic process. Because ...